Establishing a GMP-Compliant Manufacturing Facility for Innovative Cancer Immunotherapy Production
The project involves the establishment of a Good Manufacturing Practice (GMP) compliant manufacturing facility for Achilles Therapeutics, a company focused on delivering transformational cancer immunotherapies. Located in an existing warehouse in Hillingdon, London, the facility will support the production of personalised cell therapies that utilise the patient’s own immune T-cells to target specific tumour antigens.
We were appointed as Project Manager and Contract Administrator at the end of the concept design phase in July 2020. Our extensive experience in the cell and gene therapy sector enabled us to effectively manage the design and execution of the facility while adhering to the client’s aspirations.
The project involves significant alterations, including external modifications to the warehouse, the construction of clean room pods, and the addition of two mezzanine floors to accommodate laboratory and administrative support areas. Key challenges included navigating site constraints while ensuring GMP compliance and maintaining a fast-track programme to meet production targets based on incomplete clinical trials.
Despite these challenges, the project successfully obtained planning permission and maximised the use of floor space. Additionally, a bespoke procurement strategy was developed to align with business needs, allowing for a scalable production capacity from 200 doses in Phase 1 to 1,000 doses in Phase 3, ultimately leading to client satisfaction and potential repeat project opportunities.
We were appointed as Project Manager and Contract Administrator at the end of the concept design phase in July 2020. Our extensive experience in the cell and gene therapy sector enabled us to effectively manage the design and execution of the facility while adhering to the client’s aspirations.
The project involves significant alterations, including external modifications to the warehouse, the construction of clean room pods, and the addition of two mezzanine floors to accommodate laboratory and administrative support areas. Key challenges included navigating site constraints while ensuring GMP compliance and maintaining a fast-track programme to meet production targets based on incomplete clinical trials.
Despite these challenges, the project successfully obtained planning permission and maximised the use of floor space. Additionally, a bespoke procurement strategy was developed to align with business needs, allowing for a scalable production capacity from 200 doses in Phase 1 to 1,000 doses in Phase 3, ultimately leading to client satisfaction and potential repeat project opportunities.